A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
Brief description of study
If you have been newly diagnosed with high risk B-precursor acute lymphoblastic leukemia (ALL), you may qualify for a randomized trial in which participants are randomly allocated to different treatments studying the efficacy of combination chemotherapy. The goal of this trial is to investigate how well combination treatment works in patients with newly diagnosed high risk acute lymphoblastic leukemia. The study will compare disease free survival (DFS) of children with high risk B-acute lymphoblastic leukemia receiving post-induction age-adjusted intrathecal triple therapy (ITT) on a Modified Berlin-Frankfurt-Munster (MBFM) with children receiving age adjusted intrathecal (IT) methotrexate. This study has recently included a stratum to non-randomly assign "ph-like ALL" patients who have TKI sensitive mutation to evaluate the effect of dasatinib.
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
